Federal regulators say Martin Shkreli violated a lifetime pharmaceutical-industry ban through years of stock trading and online commentary. But court records show the government was already struggling to secure his compliance in 2022, raising questions about how permanent federal injunctions are monitored and enforced.
When a federal judge banned Martin Shkreli from the pharmaceutical industry for life in February 2022, the order seemed reasonably straightforward. The former drug executive was prohibited from participating in an industry where a federal court had found he orchestrated an anticompetitive scheme that drove up prescription drug prices and obstructed generic competition.
Four years later, the Federal Trade Commission and seven state attorneys general are back in court, alleging that Shkreli treated the lifetime prohibition rather less permanently than the judge intended.
In an October 13 contempt filing, regulators accuse Shkreli of trading shares in at least 60 pharmaceutical companies, broadcasting his investments online, and attempting to influence pharmaceutical businesses through public commentary and campaigns involving short positions in their stocks.
The government wants the court to order Shkreli to divest his pharmaceutical holdings, surrender profits from prohibited trading, and face escalating penalties for future violations, potentially including incarceration.
But a review of earlier court records reveals something important: this is not the first time the government has returned to court over Shkreli’s compliance with the ban.
Indeed, regulators were raising concerns about his activities within months of the original injunction.
The resulting chronology presents an accountability question extending beyond Shkreli himself. How does the federal government enforce a lifetime industry prohibition, particularly when the person subject to it continues conducting business and communicating through public financial markets?
The Original Ban
Shkreli became nationally notorious in 2015 after Turing Pharmaceuticals, subsequently known as Vyera Pharmaceuticals, acquired Daraprim and raised the medication’s price from $17.50 to $750 per tablet.
Daraprim treats toxoplasmosis, a parasitic infection that can pose serious risks to patients with weakened immune systems.
The price increase attracted widespread condemnation, but the government’s antitrust case concerned more than the price itself.
The FTC and participating states alleged that Shkreli and his associates maintained an illegal monopoly through restrictions that impeded competing manufacturers from developing generic alternatives.
Following a trial, U.S. District Judge Denise Cote ruled in January 2022 that Shkreli had violated federal and state antitrust laws.
The resulting February 4 permanent injunction barred him for life from directly or indirectly participating in the pharmaceutical industry and imposed monetary relief of up to $64.6 million.
The prohibition was broad. It covered acquiring or holding ownership interests in pharmaceutical companies and taking actions to influence or control their business or management.
The U.S. Court of Appeals for the Second Circuit upheld the lifetime ban in January 2024.
For the government, the judgment was an important antitrust victory. It was also the beginning of a much longer compliance problem.
Trouble Within the First Year
By October 2022, the FTC and state plaintiffs were already seeking additional information about Shkreli’s activities.
Their concerns centered partly on Druglike, Inc., a venture Shkreli announced in July 2022 that described itself as a software platform intended to support early-stage drug discovery.
The company raised an obvious question: could someone permanently barred from participating in the pharmaceutical industry establish a business designed to facilitate pharmaceutical research?
Regulators also questioned Shkreli’s compliance with the monetary judgment.
According to the government’s January 20, 2023, memorandum, Shkreli had paid nothing toward the judgment as of that filing.
The injunction contained provisions intended to help regulators answer precisely these kinds of questions.
Shkreli was required to submit verified compliance reports, initially within 60 days of the order and annually thereafter. The FTC and state plaintiffs could demand additional reports and obtain access to relevant records and interviews.
On October 13, 2022, regulators invoked those provisions, requesting a supplemental compliance report, supporting documents, and an interview.
What followed was a series of missed deadlines and extensions.
The government’s 2023 memorandum described repeated attempts to obtain the requested information during November and December 2022. According to the filing, Shkreli failed to produce a satisfactory supplemental report or make himself available for the requested interview.
The FTC and states consequently asked the court to compel compliance through civil contempt proceedings.
The government’s subsequent March 2023 appellate brief acknowledged that it had obtained additional information about Druglike and was investigating whether the venture violated the injunction.
The publicly available records reviewed for this article do not establish the ultimate disposition of that investigation or the earlier contempt request.
That unresolved history is significant because the latest allegations concern activity beginning during the same period.
A Lifetime Ban Meets the Livestream
According to the FTC’s October 2026 announcement, Shkreli began publicly trading pharmaceutical stocks after his release from prison in May 2022.
The new contempt filing alleges trading involving at least 60 pharmaceutical companies, accompanied by commentary on YouTube, X, and Reddit.
The government contends that the conduct violated the injunction’s restrictions on pharmaceutical-company ownership and efforts to influence corporate management.
The allegations extend beyond casual financial discussion.
Regulators say Shkreli livestreamed trading activity, explained investment strategies, and conducted public campaigns involving short positions in pharmaceutical stocks while predicting that certain companies’ clinical trials would fail.
Reporting on the filing also describes a trading challenge involving an account with a $10 million starting balance and transactions in companies including Pfizer and Moderna.
That figure describes the reported starting account balance, not an independently established amount of Shkreli’s personal wealth or profits.
The distinction matters. The government has not publicly established the complete financial scope of the alleged violations, and the FTC is seeking remedies that would require identifying and accounting for the relevant trading activity.
The alleged conduct also raises a legal distinction that the court will need to consider.
Purchasing pharmaceutical shares, taking short positions, discussing a company’s prospects, and attempting to influence corporate management are not necessarily interchangeable activities. Whether particular conduct violates the injunction depends on its exact terms and the supporting evidence.
The government’s position is that Shkreli’s activities crossed those boundaries. A contempt finding has not yet been entered on the new allegations, and Shkreli remains entitled to contest the government’s interpretation and evidence.
The Compliance Question
The most consequential aspect of the case may not be the number of stocks Shkreli allegedly traded. It may be the existence of a compliance system that regulators had already been forced to invoke.
The February 2022 injunction was not simply a declaration that Shkreli should stay away from pharmaceuticals.
It established recurring reporting obligations, authorized requests for additional information, and gave federal and state enforcers access to relevant records and interviews.
By January 2023, regulators had told the court that those mechanisms were not producing the information they required.
Now, nearly four years after the original injunction, the government alleges a pattern of prohibited activity extending back to July 2022.
Those facts do not establish that the FTC knew about every alleged stock transaction when it occurred. Nor do they demonstrate that regulators failed to investigate evidence available to them.
They do, however, leave several questions unanswered.
When did the government first identify the pharmaceutical trading now described in its contempt motion? Did Shkreli’s annual compliance reports disclose any of the transactions? What additional information did regulators obtain following the 2023 dispute? And how did the agency determine that another contempt proceeding was necessary in October 2026?
The answers could help explain whether the enforcement system operated as intended, encountered resistance that required years to resolve, or revealed shortcomings in the practical supervision of permanent industry bans.
They would also help establish how much of the latest case was developed through routine compliance monitoring and how much depended on public statements, livestreams, and other independently collected evidence.
Back to Court
The FTC and the attorneys general of New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia now want the Southern District of New York to intervene again.
Their requested sanctions include mandatory divestiture of pharmaceutical stock holdings, financial penalties based on trading profits plus prejudgment interest without offsetting losses, and escalating consequences for further violations.
The requested remedies are civil contempt measures intended to secure compliance with an existing court order. They are not a new criminal conviction, and potential incarceration would depend on further judicial proceedings and applicable legal safeguards.
The Commission authorized the action by a 1–0 vote, with FTC Chairman Andrew Ferguson recused. Commissioner Mark Meador issued a separate statement.
Daniel Guarnera, director of the FTC’s Bureau of Competition, emphasized the importance of compliance with judicial orders, warning that defendants must fulfill their obligations after a judgment.
The principle is straightforward enough.
The difficulty, as this case illustrates, lies in translating a permanent legal prohibition into sustained oversight of a person’s financial and business activities.
Shkreli’s original antitrust case demonstrated that courts can impose extraordinary remedies when conventional restrictions are insufficient to address anticompetitive conduct.
The latest contempt motion may help establish how those remedies work outside the courtroom.
After all, a lifetime ban is supposed to last a lifetime. Whether the government can reliably detect and stop prohibited conduct during that period is a separate question, and one that the next round of litigation may finally help answer.
For now, the FTC is once again asking a federal judge to enforce an order that was already supposed to be permanent.
